•  
  •  
  •  
  •  

2023-03-21 16:43:52

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • ICRA reaffirms rating of Acknit Industries Ltd
  • Faisal Islamic Bank, set to revolutionize Egypt's digital banking experience with Intellect Global Consumer Banking's CBX Platform
  • Thomas Cook India & SOTC Travel partner with LTIMindtree to launch 'Green Carpet'
  • NMDC Ltd announces price revision of Iron Ore from March 21, 2023
  • Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome

Keywords Selected:  INE326A01037

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin's Alliance Partner Caplin Receives U.S. FDA Approval for Thiamine Hydrochloride Injection USP
  • Lupin Digital Health Unveils Results of India's First Digital Therapeutics Study with ACS Patients
  • Lupin Bioresearch Centre Completes U.S. FDA Inspection with No Observations
  • U.S. FDA Completes Inspection of Lupin's Vizag Facility with No Observations
  • Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Hyderabad
  • Lupin Launches Lurasidone Hydrochloride Tablets in the United States
  • Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur
  • Lupin receives approval from US FDA for Glycopyrrolate Injection, USP
  • Lupin Launches Aptivate Champion Run for Kids Promoting Well-being and Good Eating Habits
  • Lupin receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide Tablets
  • Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care
  • Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients
  • Lupin receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets
  • Lupin gets 2 observations from USFDA for Somerset facility
  • Lupin receives approval from U.S. FDA for Prasugrel Tablets, USP
  • Lupin and Exeltis announce Reimbursement Approval of NaMuscla® in Spain
  • Lupin receives approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets
  • Lupin Launches novel fixed-dose triple drug combination DIFIZMA® DPI to Treat Inadequately Controlled Asthma
  • Lupin Diagnostics expands its footprint in Central India, Launches Regional Reference Laboratory in Indore
  • Lupin receives approval from U.S. FDA for Brivaracetam Tablets
  • Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States
  • Lupin appoints Spiro Gavaris as President of U.S. Generics Business
  • Lupin launches Rufinamide Tablets USP in the United States
  • Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Latest Post

  • ICRA reaffirms rating of Acknit Industries Ltd
  • Faisal Islamic Bank, set to revolutionize Egypt's digital banking experience with Intellect Global Consumer Banking's CBX Platform
  • Thomas Cook India & SOTC Travel partner with LTIMindtree to launch 'Green Carpet'
  • NMDC Ltd announces price revision of Iron Ore from March 21, 2023
  • Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022